RxDoctor Payments Data

Codie Vassar, MD

Psychiatry · Orange, CANPI 1538690995

Payments from drug & device makers

$1,763in general payments, 2019–2025

Across 84 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$339
  • Axsome Therapeutics, Inc.$285
  • Alkermes, Inc.$181
  • Neurocrine Biosciences, Inc.$163
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
  • Teva Pharmaceuticals USA, Inc.$136
  • plus $511 from 11 others

What the payments were for

  • Food & beverage$1,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,763 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$59,796
Medicare patients
213
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl104$161,141
IngrezzaValbenazine Tosylate11$90,097
AuvelityDextromethorphan Hbr/Bupropion85$79,742
RexultiBrexpiprazole37$59,407
TrintellixVortioxetine Hydrobromide74$51,327
VyvanseLisdexamfetamine Dimesylate76$43,759
Invega SustennaPaliperidone Palmitate13$43,630
CaplytaLumateperone Tosylate13$21,253
Aripiprazole184$12,067
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine138$11,996
AdderallDextroamphetamine/Amphetamine24$11,199
Desvenlafaxine Succinate ErDesvenlafaxine Succinate169$10,586
ConcertaMethylphenidate Hcl20$10,149
Lurasidone Hcl117$9,338
BelsomraSuvorexant19$9,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$339$161,141104 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse, Adderall$111$106,285174 claims
Neurocrine Biosciences, Inc.Ingrezza$163$90,09711 claims
Axsome Therapeutics, Inc.Auvelity$285$79,74285 claims
Otsuka America Pharmaceutical, Inc.Rexulti$90$59,40737 claims
Johnson & JohnsonInvega Sustenna, Concerta$68$53,77933 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$149$21,25313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →